#Japan #Tokyo #Stem Cell Institute #Neurotech Medical #Family Serum

A New Alliance in Neural Regeneration

In a significant development for regenerative medicine, Stem Cell Institute, based in Tokyo, has announced a partnership with Neurotech Medical from Osaka. This collaboration, set to begin on July 3, 2026, will focus on the application of cord-derived stem cell culture supernatant known as Family Serum® in the field of neural regeneration. This partnership aims to create a system for providing novel medical services that leverage the expertise of both organizations.

Overview of the Partnership

Stem Cell Institute, known for having a 99% domestic share in the perinatal tissue-derived cell banking sector, will manufacture Family Serum® under the guidance of physicians from Neurotech Medical’s partner clinics. Neurotech Medical, on the other hand, combines its patented technology ‘Targeted Neural Regenerative Medicine™’ with its unique ‘Targeted Rehabilitation™’ techniques to offer a service called ReNeuro®. Through this partnership, physicians at partner clinics will consider the use of Family Serum® as an option in the realm of free medical practice tailored to the needs of their patients.

Production of Family Serum®

Image depicting the manufacturing process of Family Serum® at the Ginza clinic for stroke and spinal injury.

Family Serum®, produced from cord-derived stem cells stored at Stem Cell Institute, is a unique service currently offered exclusively in Japan. This proprietary service is trademark registered and aims to provide new options for regenerative medicine using the child’s own umbilical cord-derived cells.

Neurotech Medical’s ReNeuro®

Neurotech Medical provides the ReNeuro® service, which integrates its innovative neural regeneration and rehabilitation techniques, offered under the supervision of qualified physicians. The partnership will allow doctors to utilize Family Serum® as one of several treatment options, based on their clinical judgment.

It is important to note that the collaboration’s impact on Stem Cell Institute’s performance is deemed minor.

Company Profiles

Stem Cell Institute

With a mission statement that echoes the need for innovative choices in maternal and child health, Stem Cell Institute operates a cell bank focused on perinatal tissues, including umbilical cords and cord blood. They aim not only to provide regenerative medical services but also to pursue the development of new treatment methods and expand their business into related realms.
Founded in August 1999, the company is listed on the Tokyo Stock Exchange Growth Market under the stock number 7096 and has a capital of 748 million yen. The company is headed by president Takafumi Shimizu.

• - Headquarters: 2F Tokyu Toranomon Building, 1-21-19 Toranomon, Minato, Tokyo 105-0001
• - Website: Stem Cell Institute

Neurotech Medical

Founded on December 27, 2019, Neurotech Medical is dedicated to enhancing the recovery potential of targeted neural circuits. Their ReNeuro® service combines the latest in regenerative medicine technology with rehabilitation, focusing on improving quality of life for patients with strokes and spinal cord injuries. They are planning to leverage cell resources and existing technologies to further advance their medical offerings.

• - Capital: 348,944,000 yen
• - President: Nagatoshi Kihouin
• - Headquarters: 216 Murakami Jitsugyo Building, 1-13-13 Chuo, Joto-ku, Osaka
• - Website: Neurotech Medical

Through this partnership, both Stem Cell Institute and Neurotech Medical are poised to make significant contributions to the field of neural regeneration and enhance treatment options in Japan.